Diagnostic Accuracy of 18FDG-PET-CT for Pacing or Defibrillation Lead Infection (ENDOTEP)
Primary Purpose
Infections of the Implanted Material, Endocarditis
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Whole-body 18FDG-PET-CT scan
Sponsored by
About this trial
This is an interventional diagnostic trial for Infections of the Implanted Material focused on measuring Pacemaker, Endocarditis, 18FDG-PET-CT, Diagnostic accuracy, Pacing or defibrillation lead
Eligibility Criteria
Inclusion Criteria:
- Both genders
- Age > 18 years
- Patient referred for extraction of cardiac material (box and lead(s)) in the context of suspicion of material infection, including a patient with pocket infection.
- Possibility of carrying out PET-CT no more than 48 hours before extraction (or, exceptionally, no more than 7 days if the patient is not under antibiotic therapy).
- Informed written consent
- Affiliation to a social security system
Exclusion Criteria:
- Pregnant or breastfeeding women
- Patients with recent implantation (less than 2 months)
- Subjects placed under judicial protection
- Subjects participating in another study that includes an exclusion period on-going at the time of screening.
Sites / Locations
- CHU de Grenoble - Hôpital A. Michallon
- CHRU de Lille - Hôpital R. Salengro
- AP-HM - Hôpital La Timone
- CHU de Bordeaux
- Clinique Pasteur
- CHU de Nancy - Hôpital de Brabois
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Whole-body 18FDG-PET-CT scan
Arm Description
18FDG-PET-CT exam will be performed in patients, with suspicion of pacing or defibrillation lead infection, hospitalized in cardiology unit.
Outcomes
Primary Outcome Measures
A semi-quantitative visual interpretation of 18FDG-PET-CT in the diagnosis of infection of intracardiac device.
Index tests will be interpreted by nuclear medicine physician from the center where the patient was included with a semi-quantitative visual score.
Moreover, all 18FDG-PET-CT recordings will be sent to the coordinating center for centralized interpretation blind to the preceding one.
All 18FDG-PET-CT recordings will be stored until interpretation, and not used for the clinical management of the patient.
Index test interpretations will be carried out blind to any other information on the patient (clinical, biology,…).
Secondary Outcome Measures
Full Information
NCT ID
NCT02251262
First Posted
September 24, 2014
Last Updated
February 8, 2022
Sponsor
University Hospital, Bordeaux
1. Study Identification
Unique Protocol Identification Number
NCT02251262
Brief Title
Diagnostic Accuracy of 18FDG-PET-CT for Pacing or Defibrillation Lead Infection
Acronym
ENDOTEP
Official Title
Assessment of Diagnostic Accuracy of 18FDG-PET-CT in Patients With Suspicion of Pacing or Defibrillation Lead Infection: a Prospective Multi-center Study
Study Type
Interventional
2. Study Status
Record Verification Date
February 2022
Overall Recruitment Status
Completed
Study Start Date
June 22, 2015 (Actual)
Primary Completion Date
June 19, 2018 (Actual)
Study Completion Date
June 19, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Bordeaux
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
With aging of the general population and broadening indications, the number of pacemaker recipients is steadily increasing. The incidence of infections of the implanted material, a dreaded major complication, is also rising. The diagnosis is evident in presence of an abscessed pocket, cutaneous breakthrough of the pulse generator or vegetations attached to the lead. On the other hand, a proportion of patients present with less specific clinical manifestations and a pacemaker recipient may be recurrently hospitalized for an infectious disorder of unknown origin despite detailed investigations. Without proof of lead infection, removal of the system without confirmation of its infection is usually proposed, despite the known morbidity and mortality associated with the extraction procedure (0.5 to 2%). Positive culture of the leads implies that the leads were involved in the infectious process. In recent years, 18FDG-PET-CT scan has made promising contributions in different areas including imaging to detect infection at different organ sites. Absence of hyperfixation of the lead, identified by 18FDG-PET/CT scan may be an accurate sign of absence of pacing system infection.
The extraction of intracardiac implanted material, when it is indicated by the current standard strategy, may result in negative bacteriological cultures in 10 to 25% of patients, even when they did not receive antibiotics before extraction.
The hypothesis of the study is that a new strategy adding 18FDG-PET-CT to the current strategy may avoid or reduce these false-positives.
Therefore it is hypothesized that the sensitivity of 18FDG-PET-CT will be high enough to avoid unnecessary extractions of uninfected leads, resulting in a high negative predictive value of the new diagnostic strategy incorporating 18FDG-PET-CT. The present study aims at providing valid estimates of diagnostic accuracy parameters of 18FDG-PET-CT, especially its sensitivity.
For this clinical study, firstly, 18FDG-PET-CT exam will be performed in patients, with suspicion of pacing or defibrillation lead infection, hospitalized in cardiology unit; secondarily, an intervention for the extraction of the intra-cardiac material, under general anesthesia, will be practiced and then a bacteriological culture for extracted material will be required.
The end of study visit is complete the last day of material extraction. The follow up will last 2 to 7 days.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infections of the Implanted Material, Endocarditis
Keywords
Pacemaker, Endocarditis, 18FDG-PET-CT, Diagnostic accuracy, Pacing or defibrillation lead
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
Outcomes Assessor
Allocation
N/A
Enrollment
235 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Whole-body 18FDG-PET-CT scan
Arm Type
Experimental
Arm Description
18FDG-PET-CT exam will be performed in patients, with suspicion of pacing or defibrillation lead infection, hospitalized in cardiology unit.
Intervention Type
Device
Intervention Name(s)
Whole-body 18FDG-PET-CT scan
Intervention Description
18FDG-PET-CT exam will be performed in patients, with suspicion of pacing or defibrillation lead infection, hospitalized in cardiology unit.
Primary Outcome Measure Information:
Title
A semi-quantitative visual interpretation of 18FDG-PET-CT in the diagnosis of infection of intracardiac device.
Description
Index tests will be interpreted by nuclear medicine physician from the center where the patient was included with a semi-quantitative visual score.
Moreover, all 18FDG-PET-CT recordings will be sent to the coordinating center for centralized interpretation blind to the preceding one.
All 18FDG-PET-CT recordings will be stored until interpretation, and not used for the clinical management of the patient.
Index test interpretations will be carried out blind to any other information on the patient (clinical, biology,…).
Time Frame
up to 48 hours after inclusion (exceptionally, up to 7 days if the patient is not under antibiotic therapy)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Both genders
Age > 18 years
Patient referred for extraction of cardiac material (box and lead(s)) in the context of suspicion of material infection, including a patient with pocket infection.
Possibility of carrying out PET-CT no more than 48 hours before extraction (or, exceptionally, no more than 7 days if the patient is not under antibiotic therapy).
Informed written consent
Affiliation to a social security system
Exclusion Criteria:
Pregnant or breastfeeding women
Patients with recent implantation (less than 2 months)
Subjects placed under judicial protection
Subjects participating in another study that includes an exclusion period on-going at the time of screening.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pierre BORDACHAR, MD
Organizational Affiliation
University Hospital, Bordeaux
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Paul PEREZ, MD, PhD
Organizational Affiliation
University Hospital, Bordeaux
Official's Role
Study Chair
Facility Information:
Facility Name
CHU de Grenoble - Hôpital A. Michallon
City
Grenoble
ZIP/Postal Code
38043
Country
France
Facility Name
CHRU de Lille - Hôpital R. Salengro
City
Lille
ZIP/Postal Code
59037
Country
France
Facility Name
AP-HM - Hôpital La Timone
City
Marseille
ZIP/Postal Code
13385
Country
France
Facility Name
CHU de Bordeaux
City
Pessac
ZIP/Postal Code
33604
Country
France
Facility Name
Clinique Pasteur
City
Toulouse
ZIP/Postal Code
31076
Country
France
Facility Name
CHU de Nancy - Hôpital de Brabois
City
Vandoeuvre Les Nancy
ZIP/Postal Code
54500
Country
France
12. IPD Sharing Statement
Learn more about this trial
Diagnostic Accuracy of 18FDG-PET-CT for Pacing or Defibrillation Lead Infection
We'll reach out to this number within 24 hrs